Guided by our Medical & Scientific Advisory Panel (MSAP), Alzheimer’s Disease International’s position is that people making decisions about treatment benefit from information that is specific, balanced, and transparent. This includes an honest discussion of the potential advantages, the limitations, and the uncertainties of each approved therapy. Approaches that combine results from multiple drugs with very different characteristics can unintentionally obscure both signs of benefit and risks, precisely at a time when people affected by MCI (Mild Cognitive Impairment) or by dementia due to Alzheimer’s disease and carers are seeking practical guidance.

Read more HERE